Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

NVX-?CoV2373 ?stored 2–8 ?°C (6 months) or ?-?20? ?°C (two years???), Spike (pre-fusion)?, efficacy 86%, dose/interval? 2/21 days .

INO-4800 is stable at room temperature for more than a year, at 37°C for more than a month, has a five-year projected shelf life at normal refrigeration temperature and does not need to be frozen during transport or storage. The ability to distribute INO-4800, and to license to global manufacturers, without the burden and expense of frozen cold-chain logistics, indicate the suitability of this DNA vaccine for international deployment at scale.

given its tolerability and immunologic profile to date, as well as lack of an anti-vector response, INO-4800 may also serve as a heterologous booster independent of the primary vaccination regimen. INO-4800 is composed of a precisely designed DNA plasmid that is administered intradermally followed by electroporation produce a well-tolerated immune response.